Drug Profile


Alternative Names: Lapaquistat acetate; T 91485; TAK 475

Latest Information Update: 01 Apr 2008

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperlipidaemics; Oxazepines; Piperidines
  • Mechanism of Action Squalene synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Mar 2008 Discontinued - Phase-II for Hyperlipidaemia in Japan (PO)
  • 28 Mar 2008 Discontinued - Phase-III for Hyperlipidaemia in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top